BioCentury
ARTICLE | Company News

LegoChem grants Bridge Biotherapeutics rights to autotaxin candidate

June 16, 2017 5:19 AM UTC

Bridge Biotherapeutics Inc. (Seongnam, South Korea) said it received exclusive, worldwide rights to a small molecule inhibitor of autotaxin (ENPP2; ATX) from LegoChem Biosciences Inc. (KOSDAQ:141080). LegoChem will receive KrW2 billion ($1.8 million) up front and up to KrW28 billion ($25.2 million) in milestones. Bridge Biotherapeutics will designate the compound as BBT-877 and is responsible for future development, while LegoChem will be responsible for backup research.

Bridge Biotherapeutics said it will develop the product to treat idiopathic pulmonary fibrosis (IPF) as its lead indication, as well as non-alcoholic steatohepatitis (NASH) and other fibrotic diseases...